1. Report Introduction 2. Atopic Dermatitis (AD) Market Overview at a Glance 2.1. Market Share Distribution of Atopic Dermatitis (AD) in 2016 2.2. Market Share Distribution of Atopic Dermatitis (AD) in 2028 3. Disease Background and Overview: Atopic Dermatitis (AD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Atopic Dermatitis (AD) in 7MM 4.3. Total Prevalent Patient Population of Atopic Dermatitis (AD) in 7MM – By Countries 5. Epidemiology of Atopic Dermatitis (AD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.1.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.1.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.1.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.1.6. Treatable Cases of the Atopic Dermatitis (AD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.4.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.4.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.4.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.4.6. Treatable Cases of the Atopic Dermatitis (AD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.5.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.5.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.5.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.5.6. Treatable Cases of the Atopic Dermatitis (AD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.6.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.6.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.6.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.6.6. Treatable Cases of the Atopic Dermatitis (AD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.7.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.7.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.7.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.7.6. Treatable Cases of the Atopic Dermatitis (AD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.8.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.8.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.8.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.8.6. Treatable Cases of the Atopic Dermatitis (AD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Atopic Dermatitis (AD) 5.9.3. Sub-Type Specific cases of the Atopic Dermatitis (AD) * 5.9.4. Sex- Specific Cases of the Atopic Dermatitis (AD) * 5.9.5. Diagnosed Cases of the Atopic Dermatitis (AD) 5.9.6. Treatable Cases of the Atopic Dermatitis (AD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Atopic Dermatitis (AD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Atopic Dermatitis (AD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Atopic Dermatitis (AD) : 7MM Market Analysis 12.1. 7MM Market Size of Atopic Dermatitis (AD) 12.2. 7MM Percentage Share of drugs marketed for Atopic Dermatitis (AD) 12.3. 7MM Market Sales of Atopic Dermatitis (AD) by Products 13. Atopic Dermatitis (AD) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Atopic Dermatitis (AD) in United States 13.1.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in United States 13.1.3. Market Sales of Atopic Dermatitis (AD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Atopic Dermatitis (AD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in Germany 13.2.1.3. Market Sales of Atopic Dermatitis (AD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Atopic Dermatitis (AD) in France 13.2.2.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in France 13.2.2.3. Market Sales of Atopic Dermatitis (AD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Atopic Dermatitis (AD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in Italy 13.2.3.3. Market Sales of Atopic Dermatitis (AD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Atopic Dermatitis (AD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in Spain 13.2.4.3. Market Sales of Atopic Dermatitis (AD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Atopic Dermatitis (AD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in United Kingdom 13.2.5.3. Market Sales of Atopic Dermatitis (AD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Atopic Dermatitis (AD) in Japan 13.3.2. Percentage Share of drugs marketed for Atopic Dermatitis (AD) in Japan 13.3.3. Market Sales of Atopic Dermatitis (AD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Atopic Dermatitis (AD) in 7MM Table 2: Total Prevalent/Incident Cases of the Atopic Dermatitis (AD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Atopic Dermatitis (AD) in United States (2016-2028) Table 5: Sex- Specific Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Table 6: Diagnosed Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Table 7: Treatable Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Table 11: Diagnosed Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Table 12: Treatable Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in France (2016-2028) Table 14: Sub-Type Specific cases of the Atopic Dermatitis (AD) in France (2016-2028) Table 15: Sex- Specific Cases of the Atopic Dermatitis (AD) in France (2016-2028) Table 16: Diagnosed Cases of the Atopic Dermatitis (AD) in France (2016-2028) Table 17: Treatable Cases of the Atopic Dermatitis (AD) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Table 21: Diagnosed Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Table 22: Treatable Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Table 26: Diagnosed Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Table 27: Treatable Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Atopic Dermatitis (AD) in UK (2016-2028) Table 30: Sex- Specific Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Table 31: Diagnosed Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Table 32: Treatable Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Table 36: Diagnosed Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Table 37: Treatable Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 42:7MM- Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 45: United States-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 48: Germany-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 51: France-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 54: Italy-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 57: Spain-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 60:UK-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Table 63: Japan-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Atopic Dermatitis (AD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Atopic Dermatitis (AD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Atopic Dermatitis (AD) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Figure 6: Diagnosed Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Figure 7: Treatable Cases of the Atopic Dermatitis (AD) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Figure 12: Treatable Cases of the Atopic Dermatitis (AD) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Atopic Dermatitis (AD) in France (2016-2028) Figure 15: Sex- Specific Cases of the Atopic Dermatitis (AD) in France (2016-2028) Figure 16: Diagnosed Cases of the Atopic Dermatitis (AD) in France (2016-2028) Figure 17: Treatable Cases of the Atopic Dermatitis (AD) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Figure 22: Treatable Cases of the Atopic Dermatitis (AD) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Figure 27: Treatable Cases of the Atopic Dermatitis (AD) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Atopic Dermatitis (AD) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Figure 31: Diagnosed Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Figure 32: Treatable Cases of the Atopic Dermatitis (AD) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Figure 37: Treatable Cases of the Atopic Dermatitis (AD) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 42:7MM- Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 45: United States-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 48: Germany-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 51: France-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 54: Italy-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 57: Spain-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 60:UK-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Atopic Dermatitis (AD) in USD MM (2016-2028) Figure 63: Japan-Market Share Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Atopic Dermatitis (AD) by Therapies in USD MM (2016-2028)